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OBJECTIVES The present study was undertaken to define physiologic limits of left ventricular hypertrophy
in elite adolescent athletes.
BACKGROUND Systematic sports training may cause increased left ventricular wall thickness (LVWT),
creating uncertainty regarding the differential diagnosis of athlete’s heart from hypertrophic
cardiomyopathy (HCM). This distinction is crucial because HCM is responsible for about
one-third of all sudden deaths in young athletes. Echocardiographic data defining athlete’s
heart are limited largely to adults, with little information specifically in adolescent athletes (14
to 18 years old), for whom the risk of sudden death from HCM is highest.
METHODS Seven hundred and twenty elite adolescent athletes (75% male) aged 15.7  1.4 years
participating in ball, racket, and endurance sports and 250 healthy sedentary controls of
similar age, gender, and body surface area underwent echocardiography.
RESULTS Compared with controls, athletes had greater absolute LVWT (9.5  1.7 mm vs. 8.4  1.4
mm; p  0.0001). Maximal LVWT exceeded predicted upper limits in 38 athletes (5%);
however, no female athlete had a LVWT 11 mm and only three trained male athletes had
absolute LVWT12 mm (0.4%). Each of the 38 athletes with a LVWT exceeding predicted
limits also showed enlarged left ventricular cavity dimension (54.4  2.1 mm; range 52 to 60
mm).
CONCLUSIONS Trained adolescent athletes demonstrated greater absolute LVWT compared with nonath-
letes. Only a small proportion of athletes exhibited a LVWT exceeding upper limits, very
rarely 12 mm, and then always with chamber enlargement. Hypertrophic cardiomyopathy
should be considered strongly in any trained adolescent male athlete with LVWT 12 mm
(females 11 mm) and nondilated left ventricle. (J Am Coll Cardiol 2002;40:1431–6)
© 2002 by the American College of Cardiology Foundation
Regular intensive physical training in some endurance sports
is associated with a physiologic increase in left ventricular
wall thickness (LVWT), cavity size, and mass (1–7). In a
small proportion of trained adult athletes, the magnitude of
LVWT may be comparable to that encountered in some
patients with mild morphologic expression of hypertrophic
cardiomyopathy (HCM) (8–10). The clinical distinction
between physiologic increases in LVWT in athletes (i.e.,
athlete’s heart) and HCM is crucial because the latter
accounts for about one-third of all exercise-related sudden
cardiac deaths in trained athletes aged 35 years old
(11–13), and disqualification from intense competitive
sports is recommended (14).
Most exercise-related sudden cardiac deaths in athletes
from HCM occur during adolescence (14 to 18 years old)
(15). However, paradoxically, definition of the normal upper
limits of physiologic hypertrophy comprising part of the
athlete’s heart syndrome has largely been based on echocar-
diographic studies performed in adult athletes (8,16,17).
Reference values for LVWT derived from adult athletes
(2,8,9,18) cannot be explicitly extrapolated to younger
athletes, who are less physically mature and are exposed to
shorter periods of intense training, for differentiating phys-
iologic LVH from HCM (19). Therefore, the present study
was undertaken to define the physiologic limits of LVWT
in elite adolescent athletes.
METHODS
Selection of athletes. Between August 1996 and Novem-
ber 2000, 720 elite adolescent athletes (age 15.7 1.4 years;
range 14 to 18 years old) underwent two-dimensional (2D)
echocardiography during the peak competitive season.
Written consent for cardiovascular evaluation was obtained
from individuals aged 16 years and from a parent/
guardian of those 16 years old. Five hundred and forty
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athletes were male (75%), 702 (98%) were Caucasian, and
2% were black. Body surface area was 1.74 0.17 m2 (range
1.09 to 2.24 m2).
Ten sporting disciplines predominantly made up the
study group: boxing, cycling, field hockey, karate, rowing,
rugby, soccer, swimming, tennis, and triathlon. Tennis and
soccer were the most commonly studied sports, and between
them accounted for 333 (46%) athletes (Table 1). Tennis
players were recruited from the British Lawn Tennis Asso-
ciation, soccer players from youth teams at clubs in the
British Premier Soccer League, boxers from prominent
amateur boxing association clubs, rugby players from British
Rugby League clubs, cyclists from large county cycling
squads, triathletes from top-10 finishers at the national U.K.
championships in 1997 and 1998, and rowers, swimmers,
and hockey and karate players from the U.K. Junior Na-
tional team. An additional 15 athletes (2%) had participated
at the national level in squash (n  3), fencing (n  2), and
track and field events (n  10).
All athletes had competed at the regional level for 4.3 
1.5 years (range 1 to 10 years) and 50% were competing at
the national level at the time of this study. The number of
hours of intensive training (assessed by questionnaire) aver-
aged 9.8  3.6 h/week (range 5 to 27 h). No athlete had
symptoms of underlying cardiovascular disease or a family
history of premature death from heart disease; none had
blood pressure 125 mm Hg systolic or 85 mm Hg
diastolic.
Controls. The control group comprised 250 healthy ado-
lescent volunteers who were students at a large secondary
education boarding school. All individuals led a relatively
sedentary lifestyle, defined as 2 h of organized physical
activity per week. Controls were of similar age, gender, and
body surface area as the trained athletes (15.5  1.2 years
[range 14 to 18]; 70% male; 1.70  0.20 m2 [range 1.17 to
2.24] respectively; NS).
Echocardiography. Two-dimensional echocardiography
was performed by two experienced technicians, with the
subjects resting in a left lateral decubitus position, using an
Acuson Computed Sonograph 128XP/10c (San Jose, Cal-
ifornia) with 3 MHz transducer. Images of the heart were
obtained in the standard parasternal long-axis and short-
axis and apical four-chamber planes, as previously described
(20). The LVWT was measured from 2D short-axis views
at end-diastole, with the greatest measurement within the
left ventricular (LV) wall defined as the maximal wall
thickness.
M-mode echocardiograms derived from 2D images in the
parasternal long axis were used for the measurement of LV
end-diastolic and systolic dimensions, left atrial diameter,
and aortic root according to American Society of Echocar-
diography standards (21). Three to five consecutive mea-
sures were made and the average was taken by a single
experienced sonographer (S.S.) blind to the identity of the
subjects.
Percent LV percentage shortening fraction was calculated
as an index of systolic function. Pulsed Doppler recordings
were performed at the distal margins of mitral valve leaflets
to provide an index of diastolic function (22). Relative wall
thickness (h/R) was calculated by dividing the sum of the
septal and posterior wall thickness at end-diastole (h) by the
LV end-diastolic diameter (R) (23). Left ventricular mass
was calculated from the LV cavity size and wall thickness in
end diastole by the formula of Devereux (24).
Predicted upper limits for normal values for the LVWT
were derived from the control group. The mean LVWT
measurements were calculated separately for males and
females in each age group. The predicted upper values were
defined as two or more standard deviations from the mean
(Table 2).
We relied largely on absolute LVWT measurements.
However, for selective comparisons of gender, age, and
different sporting disciplines, wall thickness and mass were
corrected for differences in body surface area (25,26).
Abbreviations and Acronyms
HCM  hypertrophic cardiomyopathy
h/R  relative wall thickness
LV  left ventricular
LVH  left ventricular hypertrophy
LVWT  left ventricular wall thickness
2D  two-dimensional
Table 1. Demographic Characteristics of 720 Elite Adolescent
Athletes Within Each Sporting Discipline
Sport Total % M F Age BSA
Tennis 175 24 105 70 15.4  1.2 1.7  0.8
Soccer 158 22 158 0 16.0  1.2 1.8  0.5
Swimming 83 12 38 45 15.5  0.9 1.7  0.2
Boxing 60 8 60 0 16.1  0.8 1.7  0.3
Rowing 60 8 40 20 16.3  0.9 1.9  0.3
Rugby 60 8 60 0 15.8  0.7 1.7  0.1
Cycling 40 6 40 0 15.6  1.2 1.7  0.2
Triathlon 29 4 14 15 16.6  1.1 1.7  0.2
Field hockey 22 3 0 20 15.8  1.1 1.7  0.3
Karate 20 3 20 0 15.6  0.9 1.7  0.3
Others* 15 2 5 10 15.8  0.7 1.7  0.2
*Track and field events (n  10), squash (n  3), fencing (n  2)
BSA  body surface area.
Table 2. Predicted Upper Limits of LVWT Derived From 250
Healthy Non-Athletic Controls
Age
(yrs)
Males Females
Mean  SD
(mm)
Upper Limit
(mm)
Mean  SD
(mm)
Upper Limit
(mm)
14 8.4  1.4 11 7.0  1 9
15 9.0  1.0 11 7.5  1.3 10
16 9.0  1.0 11 8.0  1.2 10
17 9.4  1.2 12 8.7  1.2 11
18 10.2  0.9 12 8.5  1.3 11
LVWT  left ventricular wall thickness.
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Electrocardiography. Electrocardiograms (ECGs) were
recorded on all athletes at the time of echocardiography
with a Marquette Hellige recorder (Milwaukee, Wisconsin)
(27). From the ECGs, Sokolow-Lyon voltage criteria (sum
of the S-wave in V1 and R-wave in V5 3.5 mV) (28) and
the Romhilt and Estes point score system (5 points) (29)
were used to identify LVH.
Statistical analysis. Data are expressed as mean  SD.
Statistical analyses were performed using unpaired Student
t test, univariate analysis of variance test with post hoc
(Bonferroni) and chi-square test. In the overall population
of 720 athletes, a multivariable linear model was used to
assess the relation between LVWT as a dependent variable
and body surface area, age, gender, and type of sport as
independent variables. A two-tailed p value 0.05 was
considered statistically significant.
RESULTS
Cardiac dimensions in elite adolescent athletes. Athletes
had a significantly greater maximal LVWT, end-diastolic
cavity size, and mass as well as left atrial diameter, when
compared with nonathletic controls (Table 3). There was no
difference in h/R between the two groups (Table 3).
Percentage differences in LVWT, cavity size, and atrial
diameter were 13%, 11%, 6%, and 5%, respectively. Abso-
lute LVWT in athletes ranged from 6 to 14 mm (Fig. 1). In
the athlete group, males had greater dimensions than
females even after correction for body size (Table 4).
Athletes with wall thickness exceeding predicted limits.
DEMOGRAPHICS. Of the 720 elite athletes, 38 (5%) had
LVWT that exceeded predicted upper limits, including 6%
of male and 5% of female athletes. The 38 athletes with a
LVWT greater than predicted were represented by each of
the sports in the study group, but most commonly rowing
(n  9), soccer (n  6), and swimming (n  5).
In the 38 athletes with a greater than predicted LVWT,
the absolute LVWT measurements ranged from 11 mm to
14 mm. Of these 38 athletes, 35 (4% of all 720 athletes) had
a LVWT12 mm but only three (0.4% of the 720 athletes)
had LVWT12 mm in absolute terms, and consistent with
HCM. Each of these three were male; two were engaged in
rowing and one in tennis. All female athletes had a LVWT
of 11 mm.
CARDIAC MORPHOLOGY. In those 38 athletes with a greater
than predicted LVWT, the pattern of LVH was concentric
(symmetric), with no athlete showing 2 mm difference in
LVWT measurements between contiguous segments of the
wall. Each of these athletes also had a greater than predicted
LV end-diastolic cavity size (i.e., 2 standard deviations from
the mean calculated from the control population) (54.4 
2.1 mm; range 52 mm to 60 mm). Also each athlete had
normal mitral inflow velocity patterns (Table 3).
Table 3. Demographic and Echocardiographic Parameters in 720 Adolescent Athletes Compared
to 250 Non-Athletic Controls*
Athletes Controls % Difference p Value
Age (yrs) 15.7  1.4 (14–18) 15.5  1.2 (14–18) 1 NS
BSA (m2) 1.74  0.17 (1.09–2.23) 1.70  0.2 (1.17–2.24) 2 NS
VS (mm) 9.4  1.3 (6–14) 8.2  1.5 (6–11) 13  0.0001
LVPW (mm) 9.3  1.3 (6–13) 8.3  1.3 (5–11) 11  0.0001
LVWT (mm) 9.6  1.3 (6–14) 8.5  1.3 (6–11) 13  0.0001
h/R ratio 0.36  0.04 (0.26–0.5) 0.35  0.05 (0.15–0.48) 3 NS
LVEDD (mm) 50.8  3.7 (40–60) 47.9  3.5 (37–54) 6  0.0001
LVMI (gm2) 113  33.3 (29–232) 86.3  24.7 (24–165) 31  0.0001
LA (mm) 32.7  4.8 (19–45) 30.9  5 (20–40) 5 0.0002
Ao (mm) 28.7  3.5 (17–40) 27.1  3.5 (19–33) 6 NS
LVSF (%) 33.1  3.5 (31–40) 31.9  3.9 (30–39) 4 NS
E-wave (m/s) 0.88  0.16 (0.5–1.7) 0.87  0.2 (0.6–1.8) 1 NS
A-wave (m/s) 0.41  0.1 (0.2–0.9) 0.45–0.16 (0.2–0.8) 9 0.005
E/A ratio 2.25  0.7 (1.0–5.5) 2.14  0.16 (1.2–4.5) 5 NS
*Expressed as mean  SD with p values reflecting unpaired Student t test.
Ao  aortic diameter; BSA  body surface area; h/R  relative wall thickness; LA  left atrial diameter; LVEDD  left
ventricular end-diastolic dimension; LVMI left ventricular mass index; LVSF left ventricular shortening fraction; LVPW
left ventricular posterior wall thickness; LVWT  left ventricular wall thickness; NS  not specified; VS  ventricular septal
thickness.
Figure 1. Distribution of left ventricular wall thicknesses in 720 junior elite
athletes (black bars) and 250 controls (white bars).
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ELECTROCARDIOGRAPHY. Of the 38 athletes with in-
creased LVWT, 31 (82%) fulfilled either Sokolow-Lyon
voltage criteria (28) or Romhilt-Estes points score (29) for
LVH. Two male athletes had minor T-wave inversions
(0.2 mV) in the inferior leads. Another 236 athletes (33%)
also showed Sokolow voltage criteria for LVH but had
normal criteria wall thickness. Deep T-wave inversions,
pathologic Q-waves (0.04 s in duration or 25% of the
height of the ensuing R-wave) and ST segment depression
were absent in all 720 athletes.
Determinants of LVWT. A multivariable linear model
was used to assess the relation between LVWT and several
demographic variables: body surface area, age, gender, type
of sport, duration of training, and athletic achievement.
After multivariable adjustment, an independent association
was found between LVWT and body surface area, age, male
gender, and type of sport (such as rowing in male athletes)
(p  0.05) (Table 5).
DISCUSSION
The differential diagnosis between athlete’s heart and HCM
represents a vital clinical dilemma because at least 10% of
adolescent patients with HCM may be at unacceptably high
risk for sudden cardiac death (30,31). For example, a false
positive diagnosis of HCM would result in unnecessary
disqualification from sport (14), thereby potentially depriv-
ing the athlete of the many physical, psychologic, and
financial benefits of athletic competition. Conversely, an
erroneous (false negative) diagnosis of athlete’s heart could
jeopardize a young life. Indeed, given the therapeutic
strategies now available to prevent sudden death, such as the
implantable cardioverter-defibrillator (31), the necessity for
earlier identification of high-risk HCM patients is now
magnified. Furthermore, accurate diagnosis of HCM offers
the opportunity to disqualify such individuals from intense
competitive sports in order to reduce their risk (14).
In this regard, the present study of more than 700 elite
adolescent athletes shows that an important minority have
an absolute increase in maximum LVWT. Whereas our
athletes showed a range in LVWT of up to 14 mm, just 4%
of the overall group was11 mm, and only 0.5% were 13
mm or 14 mm (all male). Given these observations and the
fact that none of the nonathlete controls demonstrated
LVWT 11 mm, we consider any trained adolescent
athlete with a LVWT 11 mm to probably have LVH,
justifying consideration for the diagnosis of HCM. Further-
more, because none of the 720 subjects studied had a
LVWT 14 mm, it is also reasonable to infer that a
LVWT of 15 mm or more in a highly trained adolescent
athlete probably represents HCM until proven otherwise.
Table 4. Gender Differences in Cardiac Dimensions for 720 Elite Adolescent Athletes
Males Females p Value
Age 15.6  1.2 15.4  1.12 NS
BSA (m2) 1.77  0.16 (1.34–2.23) 1.65  0.13 (1.33–1.97)  0.001
VS (mm) 9.5  1.3 (6–14) 8.3  1.1 (6–11)  0.001
LVPW (mm) 9.5  1.2 (6–13) 8.6  1.2 (6–11)  0.001
LVWT (mm) 9.8  1.2 (7–14) 8.4  1.1 (6–11)  0.001
LVWTI (mm/m2) 7.1  0.8 (4.5–9.9) 6.8  0.8 (4.6–8.5)  0.001
LVEDD (mm) 51.6  3.3 (42–60) 47.7  3.3 (41–55)  0.001
LVM (g) 211  65 (42–465) 160  50 (54–268)  0.001
LVMI (gm2) 90  25 (24–165) 75  21 (26–117)  0.001
LA (mm) 33.3  3.8 (19–45) 31.1  4.5 (20–42)  0.001
BSA body surface area; LA left atrial diameter; LVPW left ventricular wall thickness; LVWTmaximal left ventricular
wall thickness; LVWTI  maximal left ventricular wall thickness index (wall thickness/BSA1/2); LVEDD  left ventricular
end-diastolic dimension; NS  not specified; VS  ventricular septal thickness.
Table 5. LVWT and LVMI Within Each Sporting Discipline for 720 Elite Adolescent Athletes
Sport
LVWT (mm) LVWTI (mm/m2) LVMI (g/m2)
M F M F M F
Rowing 11  1.0* 9.3  1.0* 7.8  0.7* 7.1  0.8 138  39* 94  31
Triathlon 10  1.0 8.0  1.0 7.3  0.7 6.7  0.9 117  16 99  29
Swimming 9.2  1.0 8.0  1.0 7.1  0.9 6.8  0.9 118  31 101  31
Boxing 9.1  0.8 — 7.2  0.7 — 118  36 —
Cycling 9.0  1.0 — 7.3  0.6 — 118  32 —
Soccer 9.0  1.0 — 7.3  0.7 — 119  32 —
Rugby 9.0  1.0 — 7.3  0.7 — — —
Tennis 9.0  1.0 8.3  0.7 7.4  0.7 6.8  0.8 115  33 —
Karate 8.8  0.8 — 7.0  0.7 — 110  28 —
Field hockey — 8.0  1.0 — — — 98  30
*Significantly greater than in other athletes (p analysis of variance  0.001).
LVWTmaximal left ventricular wall thickness; LVWTI left ventricular wall thickness index (wall thickness/body surface
area1/2); LVMI  left ventricular mass index (mass/body surface area); —  no data available.
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We relied on absolute LVWT (rather than values nor-
malized to body surface area) so that our observations could
be placed directly in the context of clinical cardiovascular
diagnosis. Nevertheless, our multivariable analysis defined
body surface area as well as several other demographic
variables to be independent determinants of LVWT.
Differentiation of physiologic LVH from HCM. Our 38
athletes with greater than predicted LVWT showed several
echocardiographic features permitting differentiation from
HCM. First, LV cavity dimension exceeded the predicted
upper normal limits ranging from 52 to 60 mm. In contrast,
adolescents with HCM show small or normal-sized LV
chamber size; our experience with 70 adolescents with
HCM showed that none had a LV end-diastolic cavity
dimension 48 mm (32). Enlarged LV cavity dimension
occasionally encountered in adults with HCM is usually
associated with marked progressive symptoms and systolic
dysfunction and reduction in functional capacity (33). Fur-
thermore, our athletes with increased LVWT showed nor-
mal mitral inflow velocities suggesting normal diastolic
function, whereas the vast majority of patients with HCM
have abnormal LV filling patterns because of impaired
myocardial relaxation (34).
Gender differences also proved pertinent to the differen-
tial diagnosis of athlete’s heart and HCM (35). Because no
female athlete had LVWT 11 mm (which in this respect
resembled the control group), a LVWT 12 mm in trained
females with a nondilated LV in the adolescent age group
should raise the suspicion of HCM.
Finally, the precise age of the athlete may be relevant
when considering the diagnosis of HCM, in that young
affected individuals typically begin to show evidence of the
HCM phenotype by echocardiography at 13 to 14 years of
age (36). Although we cannot exclude with certainty that an
occasional young adolescent with HCM may not have the
diagnosis recognized with echocardiography, the absence of
ECG abnormalities such as ST segment depression, patho-
logic Q-waves or deep T-wave inversions in all 720 athletes
suggest that it is highly unlikely that any athlete in this study
group carried an HCM gene without evidence of the
phenotype, because abnormal ECG pattern may be evident
several years before onset of LVH in HCM (37).
Wall thickness in adult and adolescent athletes. Adoles-
cent athletes who are the subject of this study demonstrated
several similarities with previously reported populations of
older athletes (9,10). Similar to adult athletes, only a small
proportion of our junior athletes had a LVWT exceeding
predicted upper limits, and then usually associated with an
enlarged LV cavity dimension. Also, gender-related differ-
ences were evident in that adolescent male athletes showed
greater wall thickness and cavity dimensions than females
(Table 4). In terms of specific sports, and consistent with
reports in Italian athletes (17), male rowers had the greatest
LVWT measurements (Table 5), suggesting that the com-
bined stresses of intensive isometric and isotonic training
within this sporting discipline are a particularly potent
stimulus for LVH. However, most importantly, adolescent
and adult athletes clearly differed with respect to the range
of LVWT measurements, as a manifestation of physiologic
LVH. The LVWT ranged to 16 mm in adult athletes (17),
but to only 14 mm in our adolescent athletes regarded to
have physiologic LVH. This relative shift in wall thickness
between the two age groups of trained athletes is also
evident in the proportion of athletes with a LVWT 12
mm: about 2% in adults but only 0.5% in adolescents.
Such data showing important differences between ado-
lescent and adult athletes with regard to the upper limits of
physiologic LV hypertrophy underline the need for devel-
oping separate normal values for LVWT in younger ath-
letes. Furthermore, it is our aspiration that defining the
physiologic limits for LVH in the present study cohort will
facilitate differentiation of athlete’s heart from HCM in the
important subgroup of adolescent athletes, thereby enhanc-
ing the efficiency of preparticipation screening and ulti-
mately avoiding sudden deaths due to HCM. However,
because our study population was largely Caucasian, caution
should be exercised in extrapolating our findings to other
ethnic and racial athletic populations. Also, some sports
more common in the U.S., such as basketball and American
football, are not represented.
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